Detailed Information

Cited 56 time in webofscience Cited 62 time in scopus
Metadata Downloads

Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial

Authors
Park, Kwang HwanHan, Seung HwanHong, Joon PioHan, Seung-KyuLee, Doo-HyungKim, Bom SooAhn, Jae HoonLee, Jin Woo
Issue Date
Aug-2018
Publisher
ELSEVIER IRELAND LTD
Keywords
Diabetic foot ulcer; Wound healing; Epidermal growth factor; Hemoglobin A1c
Citation
DIABETES RESEARCH AND CLINICAL PRACTICE, v.142, pp 335 - 344
Pages
10
Indexed
SCI
SCIE
SCOPUS
Journal Title
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume
142
Start Page
335
End Page
344
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3299
DOI
10.1016/j.diabres.2018.06.002
ISSN
0168-8227
1872-8227
Abstract
Aims: This study was conducted to evaluate the efficacy and safety of a novel spray-applied growth factor therapy containing recombinant human epidermal growth factor (rhEGF) for the treatment of chronic diabetic foot ulcers (DFU). Methods: This study was a phase III double-blind, randomized, placebo-controlled trial. 167 adult patients at six medical centers were randomized to receive routine wound care plus either topical spray treatment with 0.005% rhEGF (n=82) or an equivalent volume of saline spray (n=85) twice a day until ulcer healing or for up to 12 weeks. Results: Demographics, medical status, and wound characteristics were comparable between rhEGF and placebo groups. More patients in the rhEGF group significantly had complete wound healing compared to placebo (73.2% versus 50.6%, respectively; P=.001). Wound healing velocity was faster in the rhEGF group (P=.029) regardless of HbA1c levels. The rhEGF group had a shorter median time to 50% ulcer size reduction (21 versus 35 days; hazard ratio=3.13, P<.001) and shorter time to complete ulcer healing (56 versus 84 days; hazard ratio=2.13, P<.001). Conclusions: This study confirms that application of spray-applied rhEGF in DFU patients results in faster healing velocity and higher complete healing rate regardless of HbA1c levels. (C) 2018 Elsevier B.V. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Plastic and Reconstructive Surgery > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Han, Seung Kyu photo

Han, Seung Kyu
Guro Hospital (Department of Plastic and Reconstructive Surgery, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE